Dermabrasion

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

| Actinic keratosis (AK)                                                                 | Actinic keratoses (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. Although most AKs do not progress to squamous cell carcinoma (SCC), AKs are a concern because the majority of cutaneous SCCs arise from pre-existing AKs, and AKs that will progress to SCC cannot be distinguished from AKs that will spontaneously resolve or persist. Accepted primary treatment modalities include cryotherapy, topical 5-fluorouracil, topical imiquimod, photodynamic therapy (e.g., amino levulinic acid [ALA], porfimer sodium), and curettage and electrodesiccation. |
| Dermabrasion                                                                       | Ablative procedure, which removes the epidermis and superficial dermis of the skin. Resurfacing is achieved by planing or sanding; usually by means of a rapidly rotating abrasive tool (wire brush, diamond fraise, or serrated wheel). Laser dermabrasion involves use of an argon laser, ultrapulse carbon dioxide (CO2) laser or flashlamp-pumped pulsed dye laser to resurface the entire face, and has been used as an alternative to standard dermabrasion in treating patients with inactive acne with disfiguring scarring. (See Limitations/Exclusions) |

Related Guidelines

- Cosmetic Surgery Procedures
- Phototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions
Guideline

Dermabrasion using controlled surgical scraping (dermaplaning) or carbon dioxide (CO₂) laser is considered medically necessary for the removal of superficial basal cell carcinomas and pre-cancerous AK lesions; both:

1. Conventional methods of removal (e.g., cryotherapy, curettage and excision) are impractical due to the number and distribution of the lesions

2. Failed trial of 5-fluorouracil (5-FU) (Efudex) or imiquimod (Aldara); unless contraindicated

Limitations/Exclusions

1. Dermabrasion is not considered medically necessary for the treatment of acne vulgaris due to insufficient evidence of therapeutic value.

2. Dermabrasion is not considered medically necessary for any of the following (list not all-inclusive):
   a. Acne scarring (case-by-case review when documentation substantiating medical necessity is submitted to the plan)
   b. Contouring/discoloration/hyperpigmentation (e.g., dermatosis papulosa nigra, rosacea)
   c. Dull complexity
   d. Ephelides (freckles)
   e. Fine/fewer lines and wrinkles
   f. Lentigines (liver spots; aka age spots)
   g. Melasma
   h. Photoaged skin
   i. Sebaceous hyperplasia (aka senile hyperplasia)
   j. Seborrheic keratoses
   k. Skin roughness
   l. Tattoo removal

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15781</td>
<td>Dermabrasion; segmental, face</td>
</tr>
<tr>
<td>15782</td>
<td>Dermabrasion; regional, other than face</td>
</tr>
<tr>
<td>15783</td>
<td>Dermabrasion; superficial, any site (eg, tattoo removal)</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C44.01</td>
<td>Basal cell carcinoma of skin of lip</td>
</tr>
<tr>
<td>C44.111</td>
<td>Basal cell carcinoma of skin of unspecified eyelid, including canthus</td>
</tr>
<tr>
<td>C44.112</td>
<td>Basal cell carcinoma of skin of right eyelid, including canthus</td>
</tr>
<tr>
<td>C44.1121</td>
<td>Basal cell carcinoma of skin of right upper eyelid, including canthus</td>
</tr>
<tr>
<td>C44.1122</td>
<td>Basal cell carcinoma of skin of right lower eyelid, including canthus</td>
</tr>
<tr>
<td>C44.119</td>
<td>Basal cell carcinoma of skin of left eyelid, including canthus</td>
</tr>
<tr>
<td>C44.1191</td>
<td>Basal cell carcinoma of skin of left upper eyelid, including canthus</td>
</tr>
<tr>
<td>C44.1192</td>
<td>Basal cell carcinoma of skin of left lower eyelid, including canthus</td>
</tr>
<tr>
<td>C44.211</td>
<td>Basal cell carcinoma of skin of unspecified ear and external auricular canal</td>
</tr>
<tr>
<td>C44.212</td>
<td>Basal cell carcinoma of skin of right ear and external auricular canal</td>
</tr>
</tbody>
</table>
C44.219  Basal cell carcinoma of skin of left ear and external auricular canal
C44.310  Basal cell carcinoma of skin of unspecified parts of face
C44.311  Basal cell carcinoma of skin of nose
C44.319  Basal cell carcinoma of skin of other parts of face
C44.41   Basal cell carcinoma of skin of scalp and neck
C44.510  Basal cell carcinoma of anal skin
C44.511  Basal cell carcinoma of skin of breast
C44.519  Basal cell carcinoma of skin of other part of trunk
C44.611  Basal cell carcinoma of skin of unspecified upper limb, including shoulder
C44.612  Basal cell carcinoma of skin of right upper limb, including shoulder
C44.619  Basal cell carcinoma of skin of left upper limb, including shoulder
C44.711  Basal cell carcinoma of skin of unspecified lower limb, including hip
C44.712  Basal cell carcinoma of skin of right lower limb, including hip
C44.719  Basal cell carcinoma of skin of left lower limb, including hip
C44.81   Basal cell carcinoma of overlapping sites of skin
C44.91   Basal cell carcinoma of skin, unspecified
D48.5    Neoplasm of uncertain behavior of skin
L57.0    Actinic keratosis

References


